Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 200 of 344 entries
View as:

Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05853172 Org: User:
Start: 03/21/23 End: 12/21/25 Due: 12/21/26

Clinical Application of Nutrition Support Package Before Hepatectomy

Phase: N/A Priority: Normal
NCT ID: NCT04218253 Org: User:
Start: 10/01/19 End: 06/30/22 Due: 06/30/23

Efficacy and Optimal Dose Selection of Intranasal Dexmedetomidine During Breast Lumpectomy Under Local Anaesthesia

Phase: N/A Priority: Normal
NCT ID: NCT02675049 Org: User:
Start: 01/31/16 End: 02/29/16 Due: 02/28/17

Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05616390 Org: User:
Start: 11/09/22 End: 11/30/25 Due: 11/30/26

Nimotuzumab in Combination With Paclitaxel Liposome and Carboplatin (TP Regimen) for the Advanced NSCLC Patients

Phase: N/A Priority: Normal
NCT ID: NCT01393080 Org: User:
Start: 03/31/11 End: 12/31/16 Due: 12/31/17

Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT07005583 Org: User:
Start: 06/30/25 End: 05/20/30 Due: 05/20/31

Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations.

Phase: N/A Priority: Normal
NCT ID: NCT03992885 Org: User:
Start: 07/01/19 End: 08/01/25 Due: 08/01/26

Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFR

Phase: N/A Priority: Normal
NCT ID: NCT01744925 Org: User:
Start: 10/31/12 End: 12/31/17 Due: 12/31/18

Serum Exosomal miRNA Predicting the Therapeutic Efficiency in Lung Squamous Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05854030 Org: User:
Start: 04/01/22 End: 08/31/23 Due: 08/31/24

Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04834986 Org: User:
Start: 04/30/21 End: 04/30/24 Due: 04/30/25

The MDA Test to Differentiate of Benign and Malignant Pulmonary Nodules

Phase: N/A Priority: Normal
NCT ID: NCT03790735 Org: User:
Start: 05/03/18 End: 06/30/19 Due: 06/30/20

Radiomics of Immunotherapeutics Response Evaluation and Prediction

Phase: N/A Priority: Normal
NCT ID: NCT04079283 Org: User:
Start: 01/01/17 End: 02/25/20 Due: 02/25/21

The Safety and Effectiveness of NEPA in Preventing Postoperative Nausea and Vomiting After General Anesthesia Gastrointestinal Cancer Surgery: A Single-Center Retrospective Study

Phase: N/A Priority: Normal
NCT ID: NCT06417567 Org: User:
Start: 05/15/24 End: 12/31/26 Due: 12/31/27

Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT04530227 Org: User:
Start: 09/25/20 End: 12/31/25 Due: 12/31/26

Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05251662 Org: User:
Start: 01/13/22 End: 01/13/25 Due: 01/13/26

Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05640791 Org: User:
Start: 12/01/22 End: 12/31/24 Due: 12/31/25

A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations

Phase: N/A Priority: Normal
NCT ID: NCT05560334 Org: User:
Start: 09/08/22 End: 09/08/25 Due: 09/08/26

Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System.

Phase: N/A Priority: Normal
NCT ID: NCT05036798 Org: User:
Start: 09/17/21 End: 12/30/23 Due: 12/30/24

Clinical Trial on the Efficacy and Safety of Chining Decoction in the Treatment of Radiation Stomatitis

Phase: N/A Priority: Normal
NCT ID: NCT02303197 Org: User:
Start: 05/31/14 End: 12/31/15 Due: 12/31/16

Serplulimab With Chemoradiotherapy for Postoperative Cervical Cancer With Risk Factors

Phase: N/A Priority: Normal
NCT ID: NCT06727617 Org: User:
Start: 11/19/24 End: 12/31/26 Due: 12/31/27

A Phase II Study of CRT Combined With QL1706 in ESCC Patients

Phase: N/A Priority: Normal
NCT ID: NCT05490719 Org: User:
Start: 08/01/22 End: 09/30/25 Due: 09/30/26

A Clinical Prospective Study to Validate a Risk Scoring Model for the HMGC After Curative Surgery

Phase: N/A Priority: Normal
NCT ID: NCT06023966 Org: User:
Start: 09/01/23 End: 03/31/26 Due: 03/31/27

Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05974059 Org: User:
Start: 08/01/23 End: 08/01/24 Due: 08/01/25

HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05621499 Org: User:
Start: 11/30/22 End: 11/30/25 Due: 11/30/26

Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.

Phase: N/A Priority: Normal
NCT ID: NCT06452602 Org: User:
Start: 06/06/24 End: 06/01/27 Due: 06/01/28